B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Fresh donor cells take on childhood leukemia in early trial
Disease control Recruiting nowThis early-stage trial is testing a one-time infusion of specially engineered immune cells from a healthy donor in 24 children and young adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The main goal is to check safety and find the…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated Jun 23, 2026 19:35 UTC
-
New combo therapy aims to wipe out leukemia cells for good
Disease control Recruiting nowThis early-stage trial tests a combination therapy for B-cell acute lymphoblastic leukemia (B-ALL). It uses specially engineered immune cells (CAR-T cells and CTLs) followed by a dendritic cell vaccine to target multiple cancer markers. The goal is to achieve a very deep remissio…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 23, 2026 19:33 UTC
-
Engineered immune cells take aim at childhood leukemia
Disease control Recruiting nowThis Phase 1 trial is testing a new type of immunotherapy for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not gone away. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack leukem…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
Experimental CAR-T therapy targets tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called CLIC-2201 for people with B-cell cancers (like certain leukemias and lymphomas) that have come back or not responded to standard care. The treatment involves collecting a patient's own immune cells, modifying them to target a pr…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
Engineered immune cells aim to stop leukemia from returning
Disease control Recruiting nowThis study tests a new type of immunotherapy using a patient's own immune cells, modified to target two leukemia markers (CD22 and CD19), as a consolidation treatment after initial remission in high-risk B-cell acute lymphoblastic leukemia. About 30 participants will receive the …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
New CAR t therapy targets hidden leukemia cells in adults
Disease control Recruiting nowThis early-stage trial tests a new type of immunotherapy (CAR T cells) in adults with B-cell acute lymphoblastic leukemia (B-ALL) who still have tiny amounts of cancer cells after their first round of treatment. The goal is to see if the therapy is safe and can eliminate these le…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
New stem cell transplant method shows promise for kids with tough blood cancers
Disease control Recruiting nowThis study tests a new way to do stem cell transplants for children with blood cancers like leukemia. It uses a half-matched family donor and removes certain immune cells from the donated cells to lower risks. The goal is to see if this method is safe and helps the child's body a…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New drug trial hopes to shrink tumors in kids with Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a drug called zilovertamab vedotin in children and young adults whose blood cancers (like certain leukemias and lymphomas) or solid tumors (neuroblastoma, Ewing sarcoma) have come back or not responded to treatment. The goal is to see if the drug is safe and can …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC
-
New 'Sandwich' strategy aims to beat leukemia relapse
Disease control Recruiting nowThis early-phase study tests a new treatment plan for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot or choose not to have a donor stem cell transplant. The approach uses the drug blinatumomab before and after a transplant of the patient's own stem cells (auto…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
Engineered immune cells take on relapsed leukemia in early trial
Disease control Recruiting nowThis study tests a new treatment called UCART22 for adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not responded to standard therapies. UCART22 uses donor immune cells that are specially designed to find and attack cancer cells carrying the CD22 marker.…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Cellectis S.A. • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
Donor immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-phase trial tests a two-step approach for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. First, patients receive donor-derived CD19 CAR T cells, then a stem cell transplant from the same donor, followed by donor-derive…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
Double-Barreled CAR t attack shows promise against tough childhood leukemia
Disease control Recruiting nowThis study is testing a new approach for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. It uses two different types of engineered immune cells (CAR T cells) that target two proteins, CD19 and CD22, on t…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
New CAR-T therapy aims to prevent relapse in childhood leukemia
Disease control Recruiting nowThis study tests a new immune cell therapy (CAR-T cells that target two proteins, CD22 and CD19) as a consolidation treatment for people with standard-risk B-cell acute lymphoblastic leukemia who are already in remission. The goal is to see if it is safe and can help prevent the …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
New CAR-T therapy SYNCAR-100 enters early human testing for tough leukemia
Disease control Recruiting nowThis early-phase study tests SYNCAR-100, a type of cell therapy (CAR-T), in 16 adults with CD19-positive B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. Participants receive four weekly injections, then are followed for safety and tu…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
New drug YK012 tested in early leukemia trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called YK012 in 46 people with B-cell acute lymphoblastic leukemia (B-ALL). The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of fighting the cancer. Participants will receive YK012 throu…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
New hope for tough blood cancers: experimental drug CC312 enters human testing
Disease control Recruiting nowThis early-stage study is testing an experimental drug called CC312 in people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose. About 44 a…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
CAR t therapy targets hidden leukemia cells to stop relapse
Disease control Recruiting nowThis study tests a CAR T-cell therapy called KTE-X19 in 60 adults with B-cell acute lymphoblastic leukemia (B-ALL) who are in remission but still have minimal residual disease (MRD) — tiny traces of cancer that standard tests miss. The goal is to see if this one-time infusion can…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 18, 2026 11:49 UTC
-
Dual-Target CAR T-Cells offer new hope for kids with relapsed leukemia
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy that targets two proteins (CD19 and CD22) on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not responded to standard treatments. Participants receive their o…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
New combo therapy aims to boost CAR t-cell success in hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests a radioactive drug (131-I apamistamab) given before CAR T-cell therapy for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. The goal is to find a safe dose and see if the combination is tolera…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New hope for tough blood cancers: drug combo trial opens
Disease control Recruiting nowThis study is for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma that has come back or not responded to treatment. Researchers are adding a new drug, capivasertib, to a standard chemotherapy and venetoclax regimen to see if it is safe and works better. T…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Second-Chance CAR-T therapy tested for blood cancer patients
Disease control Recruiting nowThis study is for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma whose CAR-T cell therapy didn't meet commercial quality standards. Researchers want to see if this slightly different product is still safe and effective. About 200 participants wil…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Personalized chemo boosts CAR T-Cell success in young leukemia patients
Disease control Recruiting nowThis study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New CAR t-cell combo shows promise against tough leukemia
Disease control Recruiting nowThis study tests two different CAR T-cell therapy approaches for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. One group gets a combination of two types of CAR T-cells (CD19 and CD22), while the other gets one type (CD19) follow…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New Dual-Target CAR t therapy offers hope for kids with tough leukemia
Disease control Recruiting nowThis study tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) on leukemia cells. It is for children whose B-cell acute lymphoblastic leukemia has come back or not responded to standard treatments. The main goal is to find a safe dose and see if the t…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Off-the-shelf cell therapy takes on aggressive blood cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called Azer-cel, a type of immune cell therapy made from donor cells, for adults with certain blood cancers that have come back or not responded to standard treatments. The goal is to see if it is safe and can shrink tumors or put the …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New drug cocktail IoVeX offers hope for relapsed leukemia patients
Disease control Recruiting nowThis early-phase trial tests whether a combination of three drugs—inotuzumab ozogamicin, venetoclax, and dexamethasone (IoVeX)—is safe for children and adults with relapsed B-cell acute lymphoblastic leukemia (B-ALL). About 28 participants will receive the drugs over one or two 2…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New CAR-T therapy offers hope for kids with hard-to-treat leukemia and lymphoma
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy made locally for children whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to treatment. The therapy uses the patient's own immune cells, modified to target and kill cancer ce…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New hope for tough leukemia: MK-1045 takes on standard therapy
Disease control Recruiting nowThis study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Can immune booster cells revive failing CAR-T therapy in leukemia?
Disease control Recruiting nowThis study tests whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 213 participants will be randomly assigned to receive eith…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New gene therapy aims to outsmart Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study tests a new gene therapy called VNX-101 for people with blood cancers (like some leukemias and lymphomas) that have returned or not responded to standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system target and…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New cocktail aims to crush resistant leukemia
Disease control Recruiting nowThis early-phase study tests a new drug (ABL001) combined with two standard drugs and a steroid for people with BCR-ABL positive B-cell acute lymphoblastic leukemia or chronic myeloid leukemia in blast crisis. The goal is to find the safest dose and see how well the combination c…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Marlise Luskin, MD • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC
-
New Dual-Target CAR-T therapy takes on tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called DuoCAR20.19.22-D95 for adults with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in the lab to better recognize and attack…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 05, 2026 12:09 UTC
-
New screening trial aims to match kids with relapsed leukemia to targeted therapies
Knowledge-focused Recruiting nowThis study screens children and young adults up to age 22 whose leukemia has returned or is hard to treat. By testing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to build a r…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: PedAL BCU, LLC • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:08 UTC
-
Leukemia treatment may erase vaccine protection—study tests if re-vaccination works
Knowledge-focused Recruiting nowThis study looks at whether children and young adults (up to age 21) treated for B-cell acute lymphoblastic leukemia with the immunotherapy drug blinatumomab still have protection from routine childhood vaccines. Researchers will measure antibody levels for diseases like tetanus,…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Arkansas Children's Hospital Research Institute • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:47 UTC
-
Real-World study tracks Blinatumomab's impact on leukemia patients
Knowledge-focused Recruiting nowThis study gathers information from 200 adults with B-cell acute lymphoblastic leukemia who received blinatumomab as part of their regular care, not in a clinical trial. Researchers will look at how many patients achieve complete remission and how long they live. The goal is to u…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:53 UTC